ClinicalTrials.gg
CompletedNCT00965731Updated Oct 28, 2015Results posted

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

A Phase 1 interventional study of Erlotinib and Erlotinib in Non-Small Cell Lung Cancer, sponsored by Pfizer. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 23
27 · median 80
Started
2010
with 2 others
Phase 1
5 of 23
none open now
Registered
3rd of 23
by date
Lead sponsor
9 of 23
Pfizer

Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 1, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About crizotinib

Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Lung Neoplasms
  • Crizotinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven diagnosis of Non-Small Cell Lung Cancer (NSCLC) that is locally advanced or and of the adenocarcinoma subtype (including mixed adenosquamous histology)
  • evident disease progression by Response Evaluation Criterion in Solid Tumors () after at least one but no more than 2 chemotherapy regimens for advanced disease
  • tumors must have as per RECIST

Exclusion criteria

Exclusion Criteria:

  • known interstitial lung disease
  • prior treatment with an agent that is known or proposed to be active by action on EGFR tyrosine kinase or c-Met/HGF (Phase 2 Portion)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Active comparator
    Erlotinib

    Drug: Erlotinib

  • Experimental
    Erlotinib + PF-02341066

    Drug: Erlotinib · Drug: PF-02341066

Interventions

  • Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)

  • For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2

  • For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)

    Phase 1, first cycle DLT includes Grade (Gr) ≥4 hematologic possible drug-related toxicities and Gr ≥3 possible drug-related febrile neutropenia. Gr ≥3 non-hematological possible drug-related toxicities (except asymptomatic lab value elevation). Gr 3/4 nausea, vomiting or diarrhea. Gr 3 hypertension considered DLT if event unmanageable by approved pharmacologic agents or symptomatic sequelae despite medical intervention. Diagnosis of interstitial lung disease. Inability to deliver at least 80 percent (%) of planned dose during cycle 1 due to possible drug-related adverse events (AEs).

    Time frame: Baseline up to Day 28

  2. Progression-Free Survival (Phase 2)

    Time in weeks from phase 2 study randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).

    Time frame: Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity

Secondary outcomes

  1. PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)

    AUCtau is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

    Time frame: Cycle 1 (C1) Day 1 (D1) i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib

  2. PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1)

    Cmax is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib

    Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib

  3. PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1)

    Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, It is used to characterize PF-02341066 CL/F after multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

    Time frame: C1D15 i.e., 15 days of giving crizotinib and erlotinib

  4. PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)

    AUCtau is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

    Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib

  5. PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1)

    Cmax is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

    Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib

  6. Molecular Weight Adjusted PF-06260182-to-PF-02341006 Ratio of AUCtau (Phase 1)

    Molecular weight adjusted PF-06260182-to-PF-02341006 ratio of AUCtau is a measure of how much PF-02341066 (parent drug) was converted to the metabolite PF-06260182 after PF-02341066 dosing. In this study, it is used to characterize the metabolite-to-parent ratio exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

    Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib

  7. Erlotinib Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)

    AUCtau is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).

    Time frame: C1D-1 i.e., 1 day prior to initiation of continuous dosing of crizotinib; C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib

  8. Erlotinib Maximum Observed Plasma Concentration (Cmax) (Phase 1)

    Cmax is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).

    Time frame: C1D-1 i.e., 1 day prior to initiation of continuous dosing of crizotinib; C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib

  9. Erlotinib Apparent Oral Clearance (CL/F) (Phase 1)

    Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, it is used to characterize erlotinib CL/F after multiple doses in combination with PF-02341066 (Cycle 1 Day 15).

    Time frame: C1D15 i.e., 15 days of giving crizotinib and erlotinib

  10. Ratio of Adjusted Means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)

    Ratio of adjusted means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.

    Time frame: C1D-1 (i.e., 1 day prior to initiation of continuous dosing of crizotinib) to C1D15 (i.e., 15 days of giving crizotinib and erlotinib)

  11. Ratio of Adjusted Means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)

    Ratio of adjusted means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.

    Time frame: C1D-1 (i.e., 1 day prior to initiation of continuous dosing of crizotinib) to C1D15 (i.e., 15 days of giving crizotinib and erlotinib)

  12. Progression-Free Survival (Phase 1)

    Time in weeks from phase 1 randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for PD), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).

    Time frame: Baseline, every 42 days until disease progression or unacceptable toxicity

  13. Duration of Response (Phase 1)

    Median duration (50 percent \[%\]) of tumor response. Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of a target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.

    Time frame: Baseline, every 42 days until disease progression or unacceptable toxicity

  14. Percentage of Participants With Objective Response (Phase 1)

    Percentage of participants during phase 1 with objective response based assessment of confirmed CR or confirmed PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.

    Time frame: Baseline, every 42 days until disease progression or unacceptable toxicity

  15. Plasma Level of Soluble Marker: c-Met Ectodomain (Phase 1)

    Levels of soluble protein biomarker c-MET was analyzed at Baseline and at Day 50.

    Time frame: Baseline and Day 50 (Cycle 3, Day 1)

  16. Plasma Level of Soluble Marker: Hepatocyte Growth Factor (HGF) Scatter Factor (Phase 1)

    Time frame: Baseline and Day 50 (Cycle 3, Day 1)

  17. Plasma Level of Soluble Marker: c-Met Ectodomain (Phase 2)

    Time frame: Baseline and Day 50 (Cycle 3, Day 1)

  18. Plasma Level of Soluble Marker: HGF Scatter Factor (Phase 2)

    Time frame: Baseline and Day 50 (Cycle 3, Day 1)

  19. Duration of Response (Phase 2)

    Median duration (50%) of tumor response. DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.

    Time frame: Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity

  20. Percentage of Participants With Confirmed CR, PR or Stable Disease (SD) at Phase 2

    Percentage of participants during phase 2 with confirmed CR, confirmed PR or SD according to RECIST 1.1. Also known as Disease Control Rate (DCR). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions. SD: neither sufficient shrinkage or increase to qualify for PR or PD.

    Time frame: Week 6 and Week 12

  21. Percentage of Participants With Objective Response (Phase 2)

    Percentage of participants during phase 2 with objective response based assessment of confirmed CR or confirmed PR according to RECIST (1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.

    Time frame: Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity

  22. Overall Survival (OS) at Phase 2

    Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.

    Time frame: Baseline until death, up to 20 months

  23. European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire (QLQ-C30) Score at Phase 2

    Phase 2 EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

    Time frame: Baseline and every 21 days, up to 20 months

  24. EORTC Quality of Life Questionnaire -Lung Cancer 13 (QLQ-LC13) Score at Phase 2

    QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, neuropathy, alopecia, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

    Time frame: Baseline and every 21 days, up to 20 months

  25. Plasma Concentration of PF-02341066 and Erlotinib (Phase 2)

    Plasma concentration of PF-02341066 and erlotinib when administered in combination during phase 2

    Time frame: Day 1 of cycles 1, 3, and 5 (i.e., up to 15 weeks) at 0 (pre-dose) and 2 to 6 hours post dose

  26. Plasma Concentration of Erlotinib (Phase 2)

    Plasma concentration of erlotinib when administered as a single agent during phase 2

    Time frame: Day 1 of cycles 1, 3, and 5 (i.e., up to 15 weeks) at 0 hours (pre-dose)

  27. Percentage of Participants With Mutations in Tumor Tissue (Phase 2)

    Tumor tissue samples collected for molecular profiling were to be analyzed to assess Kirsten rat sarcoma (KRAS) mutations, mutations, amplification and expression of Epidermal Growth Factor Receptor (EGFR) and c-Met, and echinoderm microtubule-associated protein-like 4-anaplastic large cell receptor kinase (EML4-ALK) fusion in tumors.

    Time frame: Screening

Other outcomes

  1. Maximum Tolerated Dose (MTD) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)

    MTD: the combination dose level of PF-02341066 and erlotinib in which 0/6 or 1/6 participants experienced DLT after 28 days of treatment (Cycle 1) with the next higher dose level having at least 2/3 or 2/6 participants with DLT during Cycle 1 of treatment.

    Time frame: Baseline up to 28 days (Cycle 1)

  2. Recommended Phase 2 Dose (RP2D) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)

    If no more than 1/6 participants presented with a DLT during Cycle 1 at the MTD, then this dose level was considered the RP2D. If \>1/6 participants experienced a DLT, then the previous lower level was considered the MTD and RP2D.

    Time frame: Baseline up to 28 days (Cycle 1)

07

Results

Posted Jan 14, 2013
Limitations and caveats
The sponsor terminated phase 2 of this study; no data was collected during phase 2, leading to phase 2 outcomes not analyzed. The decision was based on strategic considerations regarding the clinical program only; there were no safety concerns.

Participant flow

Participant flow — Overall Study
MilestonePF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Started720
Completed00
Not completed720
Withdrew: Death04
Withdrew: Withdrawal by subject01
Withdrew: Other715

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)

Phase 1, first cycle DLT includes Grade (Gr) ≥4 hematologic possible drug-related toxicities and Gr ≥3 possible drug-related febrile neutropenia. Gr ≥3 non-hematological possible drug-related toxicities (except asymptomatic lab value elevation). Gr 3/4 nausea, vomiting or diarrhea. Gr 3 hypertension considered DLT if event unmanageable by approved pharmacologic agents or symptomatic sequelae despite medical intervention. Diagnosis of interstitial lung disease. Inability to deliver at least 80 percent (%) of planned dose during cycle 1 due to possible drug-related adverse events (AEs).

Time frame:
Baseline up to Day 28
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)
participantsPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)23
PrimaryProgression-Free Survival (Phase 2)

Time in weeks from phase 2 study randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).

Time frame:
Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity

No measurements were reported for this outcome.

SecondaryPF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)

AUCtau is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

Time frame:
Cycle 1 (C1) Day 1 (D1) i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · ng*hr/mL
PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)
ng*hr/mLPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
C1D1 Crizotinib (N=7, 19)581.9 ± 49400.3 ± 40
C1D15 Crizotinib (N=5, 14)2274 ± 431720 ± 40
SecondaryPF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1)

Cmax is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib

Time frame:
C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · ng/mL
PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1)
ng/mLPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
C1D1 Crizotinib (N=7, 19)86.75 ± 3765.31 ± 50
C1D15 Crizotinib (N=5, 14)251.0 ± 46185.9 ± 40
SecondaryPF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1)

Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, It is used to characterize PF-02341066 CL/F after multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

Time frame:
C1D15 i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · L/hr
PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1)
L/hrPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1)88.02 ± 4387.20 ± 40
SecondaryPF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)

AUCtau is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

Time frame:
C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · ng*hr/mL
PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)
ng*hr/mLPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
C1D1 PF-06260182 (N=7, 19)16.48 ± 5814.03 ± 72
C1D15 PF-06260182 (N=5, 14)60.36 ± 6357.77 ± 66
SecondaryPF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1)

Cmax is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

Time frame:
C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · ng/mL
PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1)
ng/mLPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
C1D1 PF-06260182 (N=7, 19)2.625 ± 492.087 ± 63
C1D15 PF-06260182 (N=5, 14)7.093 ± 546.508 ± 63
SecondaryMolecular Weight Adjusted PF-06260182-to-PF-02341006 Ratio of AUCtau (Phase 1)

Molecular weight adjusted PF-06260182-to-PF-02341006 ratio of AUCtau is a measure of how much PF-02341066 (parent drug) was converted to the metabolite PF-06260182 after PF-02341066 dosing. In this study, it is used to characterize the metabolite-to-parent ratio exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.

Time frame:
C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · Ratio
Molecular Weight Adjusted PF-06260182-to-PF-02341006 Ratio of AUCtau (Phase 1)
RatioPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
C1D1 (N=7, 19)0.02748 ± 230.03395 ± 45
C1D15 (N=5, 14)0.02574 ± 270.03258 ± 31
SecondaryErlotinib Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)

AUCtau is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).

Time frame:
C1D-1 i.e., 1 day prior to initiation of continuous dosing of crizotinib; C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · ng*hr/mL
Erlotinib Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)
ng*hr/mLPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
C1D-1 Erlotinib Alone (N=7,19)23490 ± 3126880 ± 39
C1D1 Erlotinib+Crizotinib Single Dose (N=7,19)26520 ± 2530040 ± 39
C1D15 Erlotinib+Crizotinib Multiple Doses (N=5,14)41770 ± 2738910 ± 49
SecondaryErlotinib Maximum Observed Plasma Concentration (Cmax) (Phase 1)

Cmax is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).

Time frame:
C1D-1 i.e., 1 day prior to initiation of continuous dosing of crizotinib; C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · ng/mL
Erlotinib Maximum Observed Plasma Concentration (Cmax) (Phase 1)
ng/mLPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
C1D-1 Erlotinib Alone (N=7,19)1593 ± 261797 ± 36
C1D1 Erlotinib+Crizotinib Single Dose (N=7,19)1452 ± 211723 ± 38
C1D15 Erlotinib+Crizotinib Multiple Doses (N=5,14)2546 ± 242346 ± 43
SecondaryErlotinib Apparent Oral Clearance (CL/F) (Phase 1)

Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, it is used to characterize erlotinib CL/F after multiple doses in combination with PF-02341066 (Cycle 1 Day 15).

Time frame:
C1D15 i.e., 15 days of giving crizotinib and erlotinib
Reported as:
Geometric mean · L/hr
Erlotinib Apparent Oral Clearance (CL/F) (Phase 1)
L/hrPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Erlotinib Apparent Oral Clearance (CL/F) (Phase 1)2.395 ± 272.572 ± 49
SecondaryRatio of Adjusted Means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)

Ratio of adjusted means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.

Time frame:
C1D-1 (i.e., 1 day prior to initiation of continuous dosing of crizotinib) to C1D15 (i.e., 15 days of giving crizotinib and erlotinib)
Reported as:
Geometric mean · Ratio in percentage
Ratio of Adjusted Means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)
Ratio in percentagePF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Ratio of Adjusted Means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)184.80 ± 40149.41 ± 43
SecondaryRatio of Adjusted Means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)

Ratio of adjusted means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.

Time frame:
C1D-1 (i.e., 1 day prior to initiation of continuous dosing of crizotinib) to C1D15 (i.e., 15 days of giving crizotinib and erlotinib)
Reported as:
Geometric mean · Ratio in percentage
Ratio of Adjusted Means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)
Ratio in percentagePF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Ratio of Adjusted Means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)160.15 ± 49134.60 ± 27
SecondaryProgression-Free Survival (Phase 1)

Time in weeks from phase 1 randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for PD), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).

Time frame:
Baseline, every 42 days until disease progression or unacceptable toxicity

No measurements were reported for this outcome.

SecondaryDuration of Response (Phase 1)

Median duration (50 percent \[%\]) of tumor response. Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of a target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.

Time frame:
Baseline, every 42 days until disease progression or unacceptable toxicity

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Objective Response (Phase 1)

Percentage of participants during phase 1 with objective response based assessment of confirmed CR or confirmed PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.

Time frame:
Baseline, every 42 days until disease progression or unacceptable toxicity
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (Phase 1)
percentage of participantsPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Percentage of Participants With Objective Response (Phase 1)14.3 (0.4 to 57.9)5.6 (0.1 to 27.3)
SecondaryPlasma Level of Soluble Marker: c-Met Ectodomain (Phase 1)

Levels of soluble protein biomarker c-MET was analyzed at Baseline and at Day 50.

Time frame:
Baseline and Day 50 (Cycle 3, Day 1)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Plasma Level of Soluble Marker: c-Met Ectodomain (Phase 1)
nanogram per milliliter (ng/mL)PF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Baseline1560.0 ± NA1454.6 ± 303.93
C3D1 0 Hour1870.0 ± NA1525.9 ± 442.01
C3D1 6 Hour1660.0 ± NA1600.0 ± 369.05
SecondaryPlasma Level of Soluble Marker: Hepatocyte Growth Factor (HGF) Scatter Factor (Phase 1)
Time frame:
Baseline and Day 50 (Cycle 3, Day 1)

No measurements were reported for this outcome.

SecondaryPlasma Level of Soluble Marker: c-Met Ectodomain (Phase 2)
Time frame:
Baseline and Day 50 (Cycle 3, Day 1)

No measurements were reported for this outcome.

SecondaryPlasma Level of Soluble Marker: HGF Scatter Factor (Phase 2)
Time frame:
Baseline and Day 50 (Cycle 3, Day 1)

No measurements were reported for this outcome.

SecondaryDuration of Response (Phase 2)

Median duration (50%) of tumor response. DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.

Time frame:
Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Confirmed CR, PR or Stable Disease (SD) at Phase 2

Percentage of participants during phase 2 with confirmed CR, confirmed PR or SD according to RECIST 1.1. Also known as Disease Control Rate (DCR). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions. SD: neither sufficient shrinkage or increase to qualify for PR or PD.

Time frame:
Week 6 and Week 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Objective Response (Phase 2)

Percentage of participants during phase 2 with objective response based assessment of confirmed CR or confirmed PR according to RECIST (1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.

Time frame:
Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) at Phase 2

Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.

Time frame:
Baseline until death, up to 20 months

No measurements were reported for this outcome.

SecondaryEuropean Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire (QLQ-C30) Score at Phase 2

Phase 2 EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

Time frame:
Baseline and every 21 days, up to 20 months

No measurements were reported for this outcome.

SecondaryEORTC Quality of Life Questionnaire -Lung Cancer 13 (QLQ-LC13) Score at Phase 2

QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, neuropathy, alopecia, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

Time frame:
Baseline and every 21 days, up to 20 months

No measurements were reported for this outcome.

SecondaryPlasma Concentration of PF-02341066 and Erlotinib (Phase 2)

Plasma concentration of PF-02341066 and erlotinib when administered in combination during phase 2

Time frame:
Day 1 of cycles 1, 3, and 5 (i.e., up to 15 weeks) at 0 (pre-dose) and 2 to 6 hours post dose

No measurements were reported for this outcome.

SecondaryPlasma Concentration of Erlotinib (Phase 2)

Plasma concentration of erlotinib when administered as a single agent during phase 2

Time frame:
Day 1 of cycles 1, 3, and 5 (i.e., up to 15 weeks) at 0 hours (pre-dose)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Mutations in Tumor Tissue (Phase 2)

Tumor tissue samples collected for molecular profiling were to be analyzed to assess Kirsten rat sarcoma (KRAS) mutations, mutations, amplification and expression of Epidermal Growth Factor Receptor (EGFR) and c-Met, and echinoderm microtubule-associated protein-like 4-anaplastic large cell receptor kinase (EML4-ALK) fusion in tumors.

Time frame:
Screening

No measurements were reported for this outcome.

Other pre-specifiedMaximum Tolerated Dose (MTD) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)

MTD: the combination dose level of PF-02341066 and erlotinib in which 0/6 or 1/6 participants experienced DLT after 28 days of treatment (Cycle 1) with the next higher dose level having at least 2/3 or 2/6 participants with DLT during Cycle 1 of treatment.

Time frame:
Baseline up to 28 days (Cycle 1)
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)
mgAll Treated Participants (Phase 1)
PF-02341066 (BID)150
Erlotinib (QD)100
Other pre-specifiedRecommended Phase 2 Dose (RP2D) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)

If no more than 1/6 participants presented with a DLT during Cycle 1 at the MTD, then this dose level was considered the RP2D. If \>1/6 participants experienced a DLT, then the previous lower level was considered the MTD and RP2D.

Time frame:
Baseline up to 28 days (Cycle 1)
Reported as:
Number · mg
Recommended Phase 2 Dose (RP2D) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)
mgAll Treated Participants (Phase 1)
PF-02341066 (BID)150
Erlotinib (QD)100

Adverse events

Collected over Up to 28 days after the last dose of study treatment (up to approximately 20 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-02341066 (200 mg) and Erlotinib (100 mg)—2/7 (28.6%)7/7 (100%)
PF-02341066 (150 mg) and Erlotinib (100 mg)—8/20 (40%)19/20 (95%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
Disease progressionGeneral disorders0/74/20
OesophagitisGastrointestinal disorders1/70/20
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/70/20
PneumoniaInfections and infestations0/72/20
Deep vein thrombosisVascular disorders0/72/20
PancytopeniaBlood and lymphatic system disorders0/71/20
Abdominal painGastrointestinal disorders0/71/20
DiarrhoeaGastrointestinal disorders0/71/20
Viral infectionInfections and infestations0/71/20
DehydrationMetabolism and nutrition disorders0/71/20
Most frequent other events
Showing 10 of 142
Most frequent other events
EventPF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)
DiarrhoeaGastrointestinal disorders6/716/20
Dry skinSkin and subcutaneous tissue disorders5/74/20
FatigueGeneral disorders3/714/20
RashSkin and subcutaneous tissue disorders4/713/20
Decreased appetiteMetabolism and nutrition disorders3/712/20
VomitingGastrointestinal disorders4/78/20
NauseaGastrointestinal disorders3/711/20
PainGeneral disorders2/70/20
Rash pustularInfections and infestations2/70/20
HypokalaemiaMetabolism and nutrition disorders2/70/20

Baseline characteristics

Age, Customized
Age, Customized(participants)PF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)Total
18 to 44 years101
45 to 64 years51116
greater than or equal to (≥) 651910
Sex: Female, Male
Sex: Female, Male(Participants)PF-02341066 (200 mg) and Erlotinib (100 mg)PF-02341066 (150 mg) and Erlotinib (100 mg)Total
Female61319
Male178
08

Study locations

16 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • University of California, Irvine Medical Center Pharmacy
    Orange, California 92868-3298, United States
  • University of California, Irving - Medical Center
    Orange, California 92868-3298, United States
  • University of California Irvin
    Orange, California 92868, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Siteman Cancer Center -West County
    Creve Coeur, Missouri 63141, United States
  • Barnes-Jewish Hospital
    St. Louis, Missouri 63110-1094, United States
  • Washington University, School of Medicine
    St. Louis, Missouri 63110, United States
  • Siteman Cancer Center
    St. Peters, Missouri 63376, United States
  • OSU East
    Columbus, Ohio 43205, United States
  • The Ohio State University James Cancer Hospital
    Columbus, Ohio 43210, United States
  • James Care in Kenny
    Columbus, Ohio 43221, United States
  • Cancer Therapy & Research Center @ UTHSCSA
    San Antonio, Texas 78229, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Dec 2011 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2009
First posted
Aug 26, 2009
Start
Jan 2010
Primary completionActual
Dec 2011
CompletionActual
Jan 2014
Results first posted
Jan 14, 2013
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00965731
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 26, 2009
Start date
Jan 2010
Primary completion
Dec 2011
Completion
Jan 2014
Results posted
Jan 14, 2013
Last update
Oct 28, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion